drug discovery

Datavant, a fledgling spinoff from Roivant Sciences, is trying to break down information silos that often lead to poorly designed clinical trials.

Envisagenics, which was spun out of Cold Spring Harbor Laboratory, has developed a platform to help drug companies address RNA splicing errors.

Regeneron Pharmaceuticals

Since 2015, the Regeneron Genetics Center has sequenced 250,000 exomes from phenotyped individuals, identifying "human knockouts" and other large-effect mutations.

Qrativ, a joint venture of Mayo Clinic and Nference, seeks new treatments for rare diseases by coupling Mayo research with publicly available genomic data sets.

The companies will share bioinformatics and NGS expertise to speed the identification of diseases, accelerate drug discovery, and find "genomic shields."

TwoXar will work with Stanford's Asian Liver Center to identify and validate computationally-derived drug candidates that target hepatocellular carcinomas.

Cyclica will soon begin testing a commercial version of its services software this summer ahead of a full launch planned for next year.

The partners will generate and analyze disease-specific gene expression data to identify likely drug candidates for rare skin diseases.

Under the terms of the agreement, Insilico Medicine will integrate unspecified data assets and the staff of Belgian bioinformatics company InSilico Screen.

TwoXar will use the funds to expand its engineering and commercial teams and  support partnerships focused on drug candidates for metabolic and neurological diseases.

Pages

The New York City medical examiner is overseeing an effort to identify missing persons using DNA, according to the Associated Press.

Nobel laureate Günter Blobel has died at 81, the New York Times reports.

In PNAS this week: mouse model of genetically induced emphysema, gene expression signatures of circulating melanoma cells, and more.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.